These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 16455631)

  • 1. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.
    Pauleit D; Zimmermann A; Stoffels G; Bauer D; Risse J; Flüss MO; Hamacher K; Coenen HH; Langen KJ
    J Nucl Med; 2006 Feb; 47(2):256-61. PubMed ID: 16455631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results.
    Pauleit D; Stoffels G; Schaden W; Hamacher K; Bauer D; Tellmann L; Herzog H; Bröer S; Coenen HH; Langen KJ
    J Nucl Med; 2005 Mar; 46(3):411-6. PubMed ID: 15750152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma.
    Balogova S; Périé S; Kerrou K; Grahek D; Montravers F; Angelard B; Susini B; El Chater P; St Guily JL; Talbot JN
    Mol Imaging Biol; 2008; 10(6):364-73. PubMed ID: 18668293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.
    Murakami R; Uozumi H; Hirai T; Nishimura R; Shiraishi S; Ota K; Murakami D; Tomiguchi S; Oya N; Katsuragawa S; Yamashita Y
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):377-82. PubMed ID: 17321066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
    Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
    J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
    Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
    J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma.
    Imsande HM; Davison JM; Truong MT; Devaiah AK; Mercier GA; Ozonoff AJ; Subramaniam RM
    AJR Am J Roentgenol; 2011 Oct; 197(4):976-80. PubMed ID: 21940588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different distribution of (62) Cu ATSM and (18)F-FDG in head and neck cancers.
    Kositwattanarerk A; Oh M; Kudo T; Kiyono Y; Mori T; Kimura Y; Maruyama R; Fujibayashi Y; Fujieda S; Okazawa H
    Clin Nucl Med; 2012 Mar; 37(3):252-7. PubMed ID: 22310251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
    Burger IA; Zitzmann-Kolbe S; Pruim J; Friebe M; Graham K; Stephens A; Dinkelborg L; Kowal K; Schibli R; Luurtsema G; Maas B; Horn-Tutic M; Haerle SK; Wiegers J; Schaefer NG; Hany TF; von Schulthess GK
    J Nucl Med; 2014 Nov; 55(11):1778-85. PubMed ID: 25256060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET.
    Khan N; Oriuchi N; Ninomiya H; Higuchi T; Kamada H; Endo K
    Ann Nucl Med; 2004 Jul; 18(5):409-17. PubMed ID: 15462403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
    Pauleit D; Stoffels G; Bachofner A; Floeth FW; Sabel M; Herzog H; Tellmann L; Jansen P; Reifenberger G; Hamacher K; Coenen HH; Langen KJ
    Nucl Med Biol; 2009 Oct; 36(7):779-87. PubMed ID: 19720290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical values for abnormal ¹⁸F-FDG uptake in the head and neck region of patients with head and neck squamous cell carcinoma.
    Lee HS; Kim JS; Roh JL; Choi SH; Nam SY; Kim SY
    Eur J Radiol; 2014 Aug; 83(8):1455-60. PubMed ID: 24929443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies.
    Yamamoto Y; Wong TZ; Turkington TG; Hawk TC; Coleman RE
    Radiology; 2007 Jul; 244(1):263-72. PubMed ID: 17495174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
    Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer.
    Ong SC; Schöder H; Lee NY; Patel SG; Carlson D; Fury M; Pfister DG; Shah JP; Larson SM; Kraus DH
    J Nucl Med; 2008 Apr; 49(4):532-40. PubMed ID: 18344440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors.
    Abramyuk A; Wolf G; Shakirin G; Haberland U; Tokalov S; Koch A; Appold S; Zöphel K; Abolmaali N
    Acta Radiol; 2010 Sep; 51(7):793-9. PubMed ID: 20583948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.